CDK6 (Cyclin-dependent kinase 6)

These results suggest that PPI exerts antitumor effects against BxPC-3 cells by inhibiting STAT3 phosphorylation.

These results suggest that E-BVL may influence apoptotic and proliferative pathways in THP-1 leukemia cells. Overall, this study highlights B. vulgaris leaf extract as a promising natural source of bioactive compounds for anti-leukemic research, without specifically implicating berberine, which was not detected in the extract.

P1/2, N=230, Recruiting, Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | N=165 --> 230

Triple-negative breast cancer (TNBC) is highly aggressive with limited treatment options, and resistance to doxorubicin (DOX) further compromises outcomes...CBC + CBD co-therapy demonstrates synergistic efficacy against resistant TNBC by inhibiting oncogenic pathways and enhancing systemic exposure. This first study of its kind highlights CBC + CBD as a promising strategy to overcome DOX resistance in TNBC.

Comparative analyses with other gallbladder carcinoma subtypes revealed GBASC to have distinct clinical phenotypes, molecular alterations, functional characteristics, and enriched signaling pathways. Moreover, there is an urgent need for standardized treatment protocols.

Neutropenia induced by palbociclib and subsequent dose reduction did not impact the disease outcome.

Targeting these pathways with inhibitors, such as topotecan and chlorogenic acid, may provide novel treatment strategies. Furthermore, SUMOylation-driven alterations in transcription factors and DNA repair mechanisms contribute to therapy resistance. Understanding these mechanisms could pave the way for innovative interventions in glioblastoma management.

P2, N=14, Completed, Yuan Yuan | Active, not recruiting --> Completed | Trial completion date: Aug 2026 --> Nov 2025

The specific interface of cyclin D's A2' helix is unique among cyclins and its mutation slows proliferation. Taken together, our work identifies a cyclin D-substrate docking mechanism that can be targeted by novel cancer therapeutics.

Among the series, compounds 6b, 6d, and 6g demonstrated exceptional growth-inhibitory (GI) potency, achieving GI% values of 80.32%, 79.24%, and 86.40%, respectively-substantially outperforming doxorubicin (61.49%)...Several other analogues, including 6d, 6e, 6i, and 6j, also displayed potent cytotoxicity (IC50 < 10 µM), highlighting the broader therapeutic relevance of this scaffold. Collectively, these data position 6g as a compelling multi-target anticancer lead that integrates apoptosis induction, cell-cycle regulation, and angiogenesis suppression-supporting its potential for development as a next-generation broad-spectrum anticancer agent.

In the Ehrlich ascites carcinoma (EAC) model, oral administration of EEJB (400 mg/kg) significantly reduced tumor volume, packed cell volume, and viable cell count, extended mean survival time, and ameliorated tumor-induced hematological and hepatic alterations. These findings position J. betonica L. as a promising plant-derived, multi-target anticancer candidate, meriting further isolation of active principles and mechanistic exploration.